Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.19.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2017 234,076,907      
Beginning balance, value at Dec. 31, 2017 $ 234,077 $ 108,000,923 $ (110,109,000) $ (1,874,000)
Common stock issued on exercise of warrants and options, shares 1,345,710      
Common stock issued on exercise of warrants and options, value $ 1,346 69,654   71,000
Common stock issued on conversion of notes payable, shares issued 1,278,750      
Common stock issued on conversion of notes payable, value $ 1,279 97,721   99,000
Fair value of warrants and beneficial conversion feature of issued convertible notes   245,000   245,000
Fair value of options and warrants issued as compensation   143,000   143,000
Net loss     (700,000) (700,000)
Ending balance, shares at Mar. 31, 2018 236,751,367      
Ending balance, value at Mar. 31, 2018 $ 236,752 108,568,248 (110,809,000) (204,000)
Beginning balance, shares at Dec. 31, 2018 256,123,515      
Beginning balance, value at Dec. 31, 2018 $ 256,123 111,429,877 (113,168,000) (1,482,000)
Common stock issued on exercise of warrants and options, shares 1,962,153      
Common stock issued on exercise of warrants and options, value $ 1,962 170,038   172,000
Common stock issued on conversion of notes payable, shares issued 36,719,820      
Common stock issued on conversion of notes payable, value $ 36,720 1,799,280   1,836,000
Fair value of warrants and beneficial conversion feature of issued convertible notes   668,000   668,000
Fair value of options and warrants issued as compensation   99,000   99,000
Net loss     (2,282,000) (2,282,000)
Ending balance, shares at Mar. 31, 2019 294,805,488      
Ending balance, value at Mar. 31, 2019 $ 294,805 $ 114,166,195 $ (115,450,000) $ (989,000)